13F-HR filed by 5AM Venture Management, LLC
5AM Venture Management, LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 24 holding rows worth $401,432,918.
- Accession
- 0001104659-23-091386
- Filer
- CIK 1799883
- Filed
- 2023-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2023
A holdings report, 24 entries on the cover page, a total value of $401,432,918 stated on the cover page (in dollars after the unit check, H1), rows summing to $401,432,918 with VALUE read as dollars as filed, 13F file number 028-19757. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 5,798,475 | $118,346,875 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 4,408,379 | $66,742,858 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 488,442 | $21,686,825 | dollars as filed | |
| RALLYBIO CORP | 75120L100 | COM | 3,630,724 | $20,549,898 | dollars as filed | |
| VOR BIOPHARMA INC | 929033108 | COM | 6,361,723 | $19,657,724 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 357,486 | $18,231,786 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 862,286 | $15,538,394 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 490,000 | $13,822,900 | dollars as filed | |
| SCPHARMACEUTICALS INC | 810648105 | COM | 1,200,647 | $12,234,593 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 310,270 | $10,527,461 | dollars as filed | |
| VIKING THERAPEUTICS INC | 92686J106 | COM | 585,000 | $9,482,850 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 790,440 | $9,358,810 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 587,600 | $8,896,264 | dollars as filed | |
| ARVINAS INC | 04335A105 | COM | 320,000 | $7,942,400 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 665,555 | $7,381,005 | dollars as filed | |
| ANAPTYSBIO INC | 032724106 | COM | 357,733 | $7,276,289 | dollars as filed | |
| MIRATI THERAPEUTICS INC | 60468T105 | COM | 192,500 | $6,955,025 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 280,000 | $6,661,200 | dollars as filed | |
| SPRUCE BIOSCIENCES INC | 85209E109 | COM | 2,364,000 | $5,082,600 | dollars as filed | |
| Mersana Therapeutics Inc | 59045L106 | Common Stock | 1,305,000 | $4,293,450 | dollars as filed | |
| TRANSPORTATION & LOGISTI | 438083107 | COM | 4,535,919 | $4,014,288 | dollars as filed | |
| IMPEL PHARMACEUTICALS INC | 45258K109 | CMN | 2,884,791 | $3,663,685 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 152,022 | $1,803,741 | dollars as filed | |
| CIDARA THERAPEUTICS INC COM NEW | 171757107 | Stock | 1,134,511 | $1,281,997 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-23-091386 | this filing | 2023-08-14 | acceptance time not in the bulk data set |